| 1 |
34558232 | A 3D-Bioprinted Multiple Myeloma Model. | 2022 Apr |
2 |
| 2 |
34648407 | Clinical significance of SIRT3 and inflammatory factors in multiple myeloma patients with bortezomib-induced peripheral neuropathy: a cohort study. | 2021 Dec |
1 |
| 3 |
31337650 | IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma. | 2019 Sep 15 |
1 |
| 4 |
29693175 | Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro. | 2018 Jun |
2 |
| 5 |
30292410 | Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo. | 2018 Nov 2 |
1 |
| 6 |
30455994 | Biologic Agents in the Treatment of Multicentric Castleman Disease. | 2018 Oct |
1 |
| 7 |
25655379 | Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma. | 2015 Mar |
1 |
| 8 |
25791477 | Anticancer drug bortezomib increases interleukin-8 expression in human monocytes. | 2015 May 1 |
1 |
| 9 |
24619424 | The proteasome inhibitor bortezomib is a potent inducer of zinc finger AN1-type domain 2a gene expression: role of heat shock factor 1 (HSF1)-heat shock factor 2 (HSF2) heterocomplexes. | 2014 May 2 |
1 |
| 10 |
24713927 | MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells. | 2014 May 22 |
1 |
| 11 |
24908316 | Quantitative analysis of bortezomib-induced IL-8 gene expression in ovarian cancer cells. | 2014 |
1 |
| 12 |
25064746 | Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels. | 2014 Dec |
2 |
| 13 |
23063726 | Combination chemotherapy increases cytotoxicity of multiple myeloma cells by modification of nuclear factor (NF)-κB activity. | 2013 Feb |
1 |
| 14 |
21214673 | Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model. | 2011 Apr |
2 |
| 15 |
20201942 | Emergent T-helper 2 profile with high interleukin-6 levels correlates with the appearance of bortezomib-induced neuropathic pain. | 2010 Jun |
1 |
| 16 |
20663948 | Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma. | 2010 Nov |
1 |
| 17 |
19327235 | The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients. | 2009 Jan-Feb |
1 |
| 18 |
18316628 | Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. | 2008 May 1 |
1 |
| 19 |
18690088 | Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells. | 2008 Sep |
2 |
| 20 |
18989635 | Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma. | 2008 Nov |
1 |
| 21 |
19383353 | Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. | 2008 Dec |
1 |
| 22 |
16820206 | Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis. | 2007 Apr |
2 |
| 23 |
17975159 | Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. | 2007 Nov 1 |
7 |
| 24 |
16397231 | Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. | 2006 Jan 1 |
3 |
| 25 |
16584593 | [Effects of proteasome inhibitor PS-341 on the multiple cytokine expressions of mesenchymal stem cells from bone marrow in patients with multiple myeloma]. | 2006 Feb |
2 |
| 26 |
16986718 | [Bortezomib-induced tumor lysis syndrome with a remarkable elevation of LDH in a case of relapsed and therapy-resistant multiple myeloma]. | 2006 Aug |
1 |
| 27 |
15090453 | Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. | 2004 Aug 1 |
2 |
| 28 |
15217830 | Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. | 2004 Oct 15 |
1 |
| 29 |
15561686 | Multiple myeloma. | 2004 |
2 |
| 30 |
14627979 | Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. | 2003 Nov 20 |
5 |
| 31 |
11306489 | The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. | 2001 Apr 1 |
2 |
| 32 |
11740818 | Novel therapies targeting the myeloma cell and its bone marrow microenvironment. | 2001 Dec |
3 |